Phase 1 Start
CGEM: Phase 1 Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and V
October 15, 2026 · cln. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 15, 2026
- Company
- Cullinan Therapeutics, Inc. (CGEM)
- Drug
- cln
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and V
- Drug
- cln
- Indication
- AML (Acute Myeloid Leukemia)